Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
Arthritis Research & Therapy2011Vol. 13(3), pp. R75–R75
Citations Over TimeTop 1% of 2011 papers
Hans‐Peter Tony, Gerd R Burmester, Hendrik Schulze‐Koops, Mathias Grünke, J. Henes, Ina Kötter, Judith Haas, L. Unger, Svjetlana Lovric, Marion Haubitz, Rebecca Fischer‐Betz, Gamal Chehab, Andrea Rubbert‐Roth, Christof Specker, Jutta Weinerth, Julia U. Holle, Ulf Müller‐Ladner, Ramona König, Christoph Fiehn, Philip Burgwinkel, Klemens Budde, H. Sörensen, Michael J. Meurer, Martin Aringer, Bernd C. Kieseier, Cornelia Erfurt‐Berge, Michael Sticherling, Roland Veelken, Ulf Ziemann, Frank Strutz, Praxis von Wussow, Florian Meier, Nico Hunzelmann, Enno Schmidt, Raoul Bergner, Andreas Schwarting, Rüdiger Eming, Michael Hertl, Rudolf Stadler, Michael Schwarz-Eywill, Siegfried Wassenberg, Martin Fleck, Claudia Metzler, Uwe K. Zettl, J. Westphal, Stefan Heitmann, Anna Laura Herzog, Heinz Wiendl, Waltraud Jakob, Elvira Schmidt, Klaus Freivogel, Thomas Dörner, GRAID investigators
Abstract
Data from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies.
Related Papers
- → Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab(2017)34 cited
- [Rituximab for managing refractory thrombotic thrombocytopenic purpura: a report of three cases].(2013)
- → A COMMON ERROR IN USING COMBINED TREATMENT WITH RITUXIMAB AND PLASMAPHERESIS (PP) TO PREVENT OR TREAT ANTIBODY MEDIATED REJECTION (AMR)(2020)
- [Long-term prognosis of patients with steroid-dependent nephrotic syndrome treated with rituximab].(2013)
- → Treatment: Rituximab(2018)